WRF
SAGE

Waddell & Reed Financial’s Sage Therapeutics SAGE Stock Holding History

Waddell & Reed Financial’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-454,945
Closed -$32.8M – 478
2019
Q4 		$32.8M Sell
454,945
-8,720
-2% -$1.07M 0.08% 264
2019
Q3 		$65M Buy
463,665
+93,593
+25% +$15.7M 0.17% 165
2019
Q2 		$67.8M Hold
370,072
– – 0.17% 166
2019
Q1 		$58.9M Buy
370,072
+70,001
+23% +$10.1M 0.15% 185
2018
Q4 		$28.7M Buy
300,071
+63,152
+27% +$7.23M 0.08% 276
2018
Q3 		$33.5M Buy
236,919
+15,619
+7% +$2.41M 0.07% 275
2018
Q2 		$34.6M Buy
+221,300
New +$34.7M 0.08% 271

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Waddell & Reed Financial's SAGE Position: Q1 2020 in Review

Waddell & Reed Financial sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 454,945 shares — an estimated $32.8M sold.

Waddell & Reed Financial first reported a position in SAGE in Q2 2018 and held it in 7 quarters. The position peaked at $67.8M in Q2 2019. 230 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • Waddell & Reed Financial reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Waddell & Reed Financial sold 454,945 Sage Therapeutics shares in Q1 2020, an estimated $32.8M.
  • Waddell & Reed Financial first reported a position in Sage Therapeutics in Q2 2018 and held it in 7 quarters.
  • Waddell & Reed Financial's Sage Therapeutics position peaked at $67.8M in Q2 2019.
  • 230 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Waddell & Reed Financial's 13F filing for Q1 2020, filed 15 May 2020.